Illumina and Helix collaborated to assess prevalence of New SARS-CoV-2 UK variant (B117) in the U.S.
On Jan. 5, 2021, Illumina and Helix announced a collaboration to augment national surveillance infrastructure in the U.S….
On Jan. 5, 2021, Illumina and Helix announced a collaboration to augment national surveillance infrastructure in the U.S….
On Dec. 31, 2020, the World Health Organization (WHO) listed the Comirnaty COVID-19 mRNA vaccine for emergency use,…
On Dec. 31, 2020, CytoDyn announced a research manuscript submitted by Nicholas J. Agresti, M.D. had been accepted…
On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of…
On Dec. 30, 2020, Mateon Therapeutics announced that it had enrolled and treated its first sentinel Part 1…
On Dec. 28, 2020, Serum Institute of India announced the launch of India’s first indigenously developed pneumococcal vaccine…
On Dec. 22, 2020, Sorrento Therapeutics announced that an Emergency Use Authorization (EUA) Application had been submitted to…
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
On Dec. 21, 2020, the WHO reported that authorities of the United Kingdom of Great Britain and Northern…
On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of…
On Dec. 21, 2020, Quidel announced that it had received Emergency Use Authorization from the FDA to market…
On Dec. 21, 2020, Abiomed announced the first two patients in the world had been treated with the…
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
On Dec. 16, 2020, BD (Becton, Dickinson) announced that it had received pandemic orders for needles and syringes…
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
On Dec. 15, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…
On Dec.14, 2020, neuroscientists at University College London (UCL) announced they had found no significant association between COVID-19…
On Dec.14, 2020, the US Food and Drug Administration (FDA) announced they had granted Investigational New Drug (IND)…
On Dec. 14, 2020, Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of…
On Dec. 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of…
On Dev. 11, 2020, the University of Oxford reported that data from the National COVID-19 Infection Survey, done…
On Dec. 11, 2020, Eli Lilly and Incyte announced The New England Journal of Medicine had published the…
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
On Dec. 7, 2020, Matinas BioPharma announced that they planned to collaborate with the National Institute of Allergy…
On Dec. 4, 2020, Novo Nordisk announced that the FDA approved an updated label for Saxenda (liraglutide) injection…
On Dec. 3, 2020, the U.S. Department of Defense in coordination with the Department of HHS, awarded a…
On Dec. 3, 2020, a new study by researchers at the University of British Columbia and BC Children’s…
On Dec. 3, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…
On Dec. 2, 2020, Oxford Immunotec announces an exclusive distribution agreement with RIKEN Genesis in Japan. Under the…